- Home
- EQ vs GREE Comparison
EQ vs GREE Comparison
Compare EQ & GREE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- GREE
- Stock Information
- Founded
- EQ 2017
- GREE 1937
- Country
- EQ United States
- GREE United States
- Employees
- EQ N/A
- GREE N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- GREE Investment Bankers/Brokers/Service
- Sector
- EQ Health Care
- GREE Finance
- Exchange
- EQ Nasdaq
- GREE Nasdaq
- Market Cap
- EQ 24.8M
- GREE 23.4M
- IPO Year
- EQ 2018
- GREE N/A
- Fundamental
- Price
- EQ $0.59
- GREE $1.85
- Analyst Decision
- EQ Buy
- GREE Strong Buy
- Analyst Count
- EQ 2
- GREE 1
- Target Price
- EQ $5.00
- GREE $4.00
- AVG Volume (30 Days)
- EQ 117.7K
- GREE 514.7K
- Earning Date
- EQ 11-13-2024
- GREE 11-07-2024
- Dividend Yield
- EQ N/A
- GREE N/A
- EPS Growth
- EQ N/A
- GREE N/A
- EPS
- EQ N/A
- GREE N/A
- Revenue
- EQ $45,914,000.00
- GREE $64,382,999.00
- Revenue This Year
- EQ $4.76
- GREE N/A
- Revenue Next Year
- EQ N/A
- GREE N/A
- P/E Ratio
- EQ N/A
- GREE N/A
- Revenue Growth
- EQ 7.70
- GREE N/A
- 52 Week Low
- EQ $0.56
- GREE $1.62
- 52 Week High
- EQ $3.25
- GREE $9.26
- Technical
- Relative Strength Index (RSI)
- EQ 33.48
- GREE 36.09
- Support Level
- EQ $0.56
- GREE $1.80
- Resistance Level
- EQ $0.67
- GREE $2.24
- Average True Range (ATR)
- EQ 0.05
- GREE 0.15
- MACD
- EQ -0.00
- GREE -0.04
- Stochastic Oscillator
- EQ 15.79
- GREE 7.23
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About GREE Greenidge Generation Holdings Inc.
Greenidge Generation Holdings Inc owns and operates a vertically integrated cryptocurrency data center and power generation company. The company owns and operates facilities at two locations: the Town of Torrey, New York, and Spartanburg, South Carolina. The cryptocurrency data center operations generate revenue in the form of bitcoin by earning bitcoin as rewards and transaction fees for supporting the bitcoin network with application-specific integrated circuit computers (ASICs or miners) owned or leased by the company.